AJAnnarani Jose

Annarani Jose

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annarani Jose has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative performance of first-void urine and self-collected vaginal swabs against clinician-collected cervical samples using 2 HPV real-time assays in Indian women

    by Rajeswari A, John Dickson Calvin Devadasan, Vinotha Thomas, Dhanya Susan Thomas, Anitha Thomas, Annie Prasanthi Vijjeswarapu, Shiny Nirupama, Karthick Nithyanandhan, Annarani Jose, Susanne A. Pulimood, et al.

    To enhance participation of women in cervical cancer (CC) screening, we compared high-risk human papillomavirus (HR-HPV) DNA testing of first-void urine (FVU) and self-collected vaginal swabs (SCVSs) to the gold standard clinician collected cervical specimens (CCCSs). In this cross-sectional study, consecutive consenting women (n=295) identified for CC screening mainly from Gynaecology-Oncology out-patient clinics were enrolled from May to October 2024. All were educated to provide self-samples (FVU, SCVS) followed by CCCS. All samples were tested for HR-HPV by 2 real-time polymerase chain reaction assays: Alinity m HR-HPV assay and Allplex™ II HPV HR assay. Awareness of CC, its screening, prevention and acceptability of self-sampling methods were assessed through a questionnaire. All sample types showed identical concordance (93.9%)/discordance (6.1%) across both real-time assays. Using Alinity m, sensitivity and specificity of FVU vs. CCCS was similar to SCVS vs. CCCS, i.e., 83.3% (95% confidence interval [CI]=68.64%-93.03%) and 98% (95% CI=95.45%-99.36%) respectively. With Allplex, sensitivity and specificity of FVU vs. CCCS was 84.78% (95% CI=71.13%-93.66%) and 97.19% (95% CI=94.29%-98.86%) respectively; and that of SCVS vs. CCCS was 97.83% (95% CI=88.47%-99.94%) and 95.98% (95% CI=92.74%-98.06%) respectively. Majority were unaware of CC (86.4%), its screening (98.6%) or its prevention (96.9%). Majority of women (92%) preferred FVU for CC if screened at regular intervals. This study shows a favorable performance of FVU and SCVS in both assays. FVU is a scalable, non-invasive, acceptable and feasible alternative to CCCS, with the potential to intensify CC screening programs in low- and middle-income countries.